Superworth

Edgewise Therapeutics EPS EWTX

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$1.85
Latest quarter, Q2 FY26
−$0.53
Fiscal year 2025
−$1.63

Edgewise Therapeutics' earnings per share was −$1.85 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.53.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.63n/a
FY2024−$1.45n/a
FY2023−$1.58n/a
FY2022−$1.27n/a
FY2021−$5.10n/a
FY2020−$24.97n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.53n/a−$1.85
Q1 FY26−$0.46n/a−$1.66
Q4 FY25−$0.47n/a−$1.63
Q3 FY25−$0.39n/a−$1.58
Q2 FY25−$0.34n/a−$1.55
Q1 FY25−$0.43n/a−$1.55
Q4 FY24−$0.42n/a−$1.45
Q3 FY24−$0.36n/a−$1.50
Q2 FY24−$0.34n/a−$1.55
Q1 FY24−$0.33n/a−$1.55
Q4 FY23−$0.47n/a−$1.58
Q3 FY23−$0.41n/a−$1.42

Against its peers

Companies in Drug Manufacturers - General nearest Edgewise Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
EWTXEdgewise Therapeutics−$1.85
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
LQDALiquidia$1.39
OGNOrganon$0.77−71% a year
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
AMRXAmneal Pharmaceuticals$0.49+4800% a year
NRIXNurix Therapeutics$2.31
ALKSAlkermes plc.$0.38−82% a year
PBHPrestige Consumer Healthcare$3.57−16% a year
Peer median$1.18

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Edgewise Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.